ALNY vs TAP · P/E 76, rev $1.29B vs rev $13.04B
Alnylam Pharmaceuticals Inc (ALNY) versus TAP (TAP) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
TAP (TAP) common stock.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported TAP revenue for 2025-12-31 was $13.04B. Net income was -$2.14B. Revenue was down 5.1% from 2024-12-31 to 2025-12-31. TAP currently screens at market cap $0.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. TAP currently screens at market cap $0.
Not investment advice. Open the ALNY and TAP stock pages for the full models.
Not investment advice.